|

Symptoms Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From Electronic Patient-Reported Outcomes

RECRUITINGSponsored by Qian Chu
Actively Recruiting
SponsorQian Chu
Started2024-06-01
Est. completion2025-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07131670

Summary

This prospective observational study aims to evaluate symptom burden and symptom clusters among lung cancer patients undergoing definitive concurrent chemoradiotherapy (CRT), based on electronic patient-reported outcomes (ePROs). Patients will complete the validated MDASI-LC and EQ-5D instruments weekly from baseline through the end of CRT and for 12 weeks post-treatment. The study will characterize the longitudinal trajectories of symptom severity and interference, identify distinct symptom clusters and their temporal patterns, and explore patient-level predictors of symptom burden. The findings may support the development of personalized symptom management strategies and improve quality of life during and after CRT.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Pathologically confirmed unresectable stage III NSCLC or limited-stage SCLC
* Age ≥ 18 years
* Receiving definitive chemoradiotherapy
* Able and willing to complete electronic questionnaires
* Provided written informed consent

Exclusion Criteria:

* Severe comorbidities (heart, liver, kidney)
* Psychiatric illness or cognitive impairment
* Prior chest or mediastinal radiotherapy

Conditions4

CancerChemoradiotherapyLung CancerPatient-Reported Outcomes (PRO)

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.